Changes in A1C levels are significantly associated with changes in levels of the cardiovascular risk biomarker hs-CRP: Results from the SteP study

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 2084-2089

  Schnell, Oliver ^a   Amann Zalan, Ildiko ^b   Jelsovsky, Zhihong ^c   Moritz, Annette ^b   Bermejo, Justo L ^d   Parkin, Christopher G ^e   Schweitzer, Matthias A ^b   Fisher, Lawrence ^f   Polonsky, William H ^g  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c BioStat International Inc   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e CGParkin Communications Inc   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD ANALYSIS EQUIPMENT; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; COMPUTER SYSTEM; CONTROLLED STUDY; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF MONITORING;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84886047601     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1711     Document Type: Article

References (32)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl JMed 2008;359:1577-1589
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
4. Nathan DM, Cleary PA, Backlund JY., et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
5. Sarwar N, Gao P, Seshasai S.R., et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375: 2215-2222
6. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-2011
7. Kervinen H, Palosuo T, Manninen V, Tenkanen L, Vaarala O, Mänttäri M. Joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J 2001;141:580-585
8. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-2485
9. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334
10. OtterW, Winter M, DoeringW, Standl E, Schnell O. C-reactive protein in diabetic and nondiabetic patients with acute myocardial infarction. Diabetes Care 2007;30:3080-3082
11. King DE, Mainous AG 3rd, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 2003;26:1535-1539
12. Weber C, Schnell O. The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther 2009;11: 623-633
13. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010;12:288-298
14. Ceriello A, Testa R. Antioxidant antiinflammatory treatment in type 2 diabetes. Diabetes Care 2009;32(Suppl. 2):S232-S236
15. Yokoyama H, Inoue T, Node K. Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance. Diabetes Res Clin Pract 2009;83:77-82
16. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl.):S1-S9
17. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843
18. Polonsky WH, Fisher L, Schikman CH., et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care 2011;34:262-267
19. PolonskyW, Fisher L, SchikmanC., et al.The value of episodic, intensive blood glucose monitoring in non-insulin treated persons with Type 2Diabetes: design of the Structured Testing Program (STeP) study, a clusterrandomised, clinical trial [NCT00674986]. BMC Fam Pract 2010;11:37
20. PolonskyWH, Fisher L, Schikman CH., et al. Astructured self-monitoring of blood glucose approach in type 2 diabetes encouragesmore frequent, intensive, and effective physician interventions: results from the STeP study. Diabetes Technol Ther 2011;13:797-802
21. World Medical Association Declaration of Helsinki. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277:925-926
22. Pearson TA, Mensah GA, Alexander RW., et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511
23. SAS Institute. SAS/STAT User's Guide. 8 ed. Cary, NC, SAS Institute, Inc., 1999
24. Fitzmaurice G, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ, John W. Wiley and Sons, 2004
25. Little RJA, Rubin DB. Statistical Analysis with Missing Data. 2nd ed. Hoboken, NJ, John W. Wiley and Sons, 2002
26. Baron RM, Kenny DA. The moderatormediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173-1182
27. Oh J, Teoh H, Leiter LA. Should C-reactive protein be a target of therapy? Diabetes Care 2011;34(Suppl. 2):S155-S160
28. Ceriello A, Quagliaro L, Piconi L., et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004;53: 701-710
29. Esposito K, Ciotola M, Carleo D., et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008;93:1345-1350
30. Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94:410-415
31. Parkin CG, Buskirk A, Hinnen DA, Axel- Schweitzer M. Results that matter: structured vs. unstructured self-monitoring of blood glucose in type 2 diabetes. Diabetes Res Clin Pract 2012;97:6-15
32. Lalic N, Tankova T, NourredineM, Parkin C, Schweppe U, Amann-Zalan I. Value and utility of structured self-monitoring of blood glucose in real world clinical practice: findings from a multinational observational study. Diabetes Technol Ther 2012;14:338-343